Biohaven's Nurtec Receives the US FDA's Approval for Treatment of Migraine in Adults
Shots:
- The approval is based on P-III study (Study 303) and Study 201 which involves assessing of Nurtec vs PBO in patients with migraine
- The study resulted in well-tolerated results. Additionally- Biohaven launched a broad suite
- Nurtec (rimegepant- 75mg) is a first and only calcitonin gene-related peptide (CGRP) receptor antagonist approved by the US FDA to treat migraine in adults
Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com